Bethany Sensenig C.M.A., M.B.A. Net Worth

The estimated Net Worth of Bethany Sensenig is at least $13.9 Thousand dollars as of 21 April 2023. Ms Sensenig owns over 9,100 units of 9 Meters Biopharma stock worth over $2,875 and over the last 3 years she sold NMTR stock worth over $11,011.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms A NMTR stock SEC Form 4 insiders trading

Ms has made over 1 trades of the 9 Meters Biopharma stock since 2023, according to the Form 4 filled with the SEC. Most recently she sold 9,100 units of NMTR stock worth $11,011 on 21 April 2023.

The largest trade she's ever made was selling 9,100 units of 9 Meters Biopharma stock on 21 April 2023 worth over $11,011. On average, Ms trades about 1,820 units every 0 days since 2022. As of 21 April 2023 she still owns at least 41,077 units of 9 Meters Biopharma stock.

You can see the complete history of Ms Sensenig stock trades at the bottom of the page.

Ms. Bethany Sensenig C.M.A., M.B.A. biography

Bethany Sensenig C.M.A., M.B.A. is the Chief Financial Officer at 9 Meters Biopharma.

What's Ms A's mailing address?

Bethany's mailing address filed with the SEC is C/O SUPERNUS PHARMACEUTICALS, INC., 9715 KEY WEST AVENUE, ROCKVILLE, MD, 20850.

Insiders trading at 9 Meters Biopharma

Over the last 5 years, insiders at 9 Meters Biopharma have traded over $20,934,964 worth of 9 Meters Biopharma stock and bought 2,247,050 units worth $1,572,701 . The most active insiders traders include Israel Gp Ltd.Orbi Med Isra..., Mark A Sirgo, and John Temperato. On average, 9 Meters Biopharma executives and independent directors trade stock every 35 days with the average trade being worth of $45,283. The most recent stock trade was executed by Bethany Sensenig on 21 April 2023, trading 9,100 units of NMTR stock currently worth $11,011.

What does 9 Meters Biopharma do?

9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders. The company is developing Larazotide, an 8-amino acid peptide, which is in Phase 3 clinical trial for the treatment of celiac disease, as well as in Phase IIa clinical trial for treatment of multi-system inflammatory syndrome; and Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 2 clinical trial to treat short bowel syndrome. It also develops NM-102, a small molecule peptide; NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease; NM-136, a humanized monoclonal antibody for targeted obesity disorders; and NM-004, a double-cleaved mesalamine with an immunomodulator for rare and/or orphan indications. The company is based in Raleigh, North Carolina.

Complete history of Ms Sensenig stock trades at Supernus Pharmaceuticals Inc and 9 Meters Biopharma

9 Meters Biopharma executives and stock owners

9 Meters Biopharma executives and other stock owners filed with the SEC include:

• John Temperato,
  Pres, CEO & Director
• Dr. Patrick H. Griffin,
  Chief Medical Officer
• Edward J. Sitar CPA, CPA,
  Chief Financial Officer
• Sarah Liu M.B.A.,
  Chief Commercial Officer
• Albert J. Medwar M.B.A., MBA,
  Sr. VP of Investor Relations & Corp. Communications
• Bethany Sensenig C.M.A., M.B.A.,
  Chief Financial Officer
• Dr. Nir Barak M.D.,
  Sr. VP of Scientific Affairs
• Dr. Elena Verdu M.D., Ph.D.,
  Clinical & Scientific Advisor and Consultant
• Dr. Ciaran P. Kelly M.D.,
  Clinical & Scientific Advisor and Consultant
• Joseph A. Murray,
  Clinical & Scientific Advisor and Consultant
• Dr. Peter H. R. Green M.D.,
  Clinical & Scientific Advisor and Consultant
• Dr. Nir Barak,
  Sr. VP of Scientific Affairs
• Jerry Gardner,
  Head of Clinical Strategy
• Sireesh Appajosyula Pharm.D.,
  Sr. VP of Corp. Devel. & Operations
• Samantha Ventimiglia,
  Director
• Bethany Sensenig,
  Chief Financial Officer
• John Temperato,
  Chief Executive Officer
• Edward J Sitar,
  Chief Financial Officer
• Lorin K Johnson,
  Director
• Israel Gp Ltd.Orbi Med Isra...,
  
• Nissim Darvish,
  Director
• Sandeep Laumas,
  Director
• Mark A Sirgo,
  Director
• Saira Ramasastry,
  Director
• Roy Proujansky,
  Director
• Yehuda Michael Rice,
  Director
• Jay P. Madan,
  President
• Anthony E Iii Maida,
  Director
• Michael T. Constantino,
  Director